Fulgent Genetics
Market Cap
US$204.3m
Last Updated
2019/09/19 01:02 UTC
Data Sources
Company Financials +
Executive Summary
Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information.
Snowflake
Fundamentals
Excellent balance sheet with high growth potential.
Risks
- Fulgent Genetics has significant price volatility in the past 3 months.
- Fulgent Genetics is covered by less than 3 analysts.
Similar Companies
Share Price & News
How has Fulgent Genetics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-3.3%
NasdaqGM:FLGT
-1.2%
US Healthcare
-0.02%
US Market
1 Year Return
231.3%
NasdaqGM:FLGT
-9.4%
US Healthcare
1.6%
US Market
FLGT outperformed the Healthcare industry which returned -8.4% over the past year.
FLGT outperformed the Market in United States of America which returned 1.9% over the past year.
Share holder returns
| FLGT | Industry | Market | |
|---|---|---|---|
| 7 Day | -3.3% | -1.2% | -0.02% |
| 30 Day | -7.1% | -2.2% | 2.7% |
| 90 Day | 97.3% | -1.5% | 1.4% |
| 1 Year | 231.3%231.3% | -8.0%-9.4% | 3.8%1.6% |
| 3 Year | n/a | 28.7%23.5% | 45.2%35.8% |
| 5 Year | n/a | 62.7%53.0% | 61.8%44.1% |
Price Volatility Vs. Market
How volatile is Fulgent Genetics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
Do Directors Own Fulgent Genetics, Inc. (NASDAQ:FLGT) Shares?1 month ago | Simply Wall St
Have Fulgent Genetics, Inc. (NASDAQ:FLGT) Insiders Been Selling Their Stock?1 month ago | Simply Wall St
Investors Who Bought Fulgent Genetics (NASDAQ:FLGT) Shares A Year Ago Are Now Up 38%Valuation
Is Fulgent Genetics undervalued based on future cash flows and its price relative to the stock market?
34%
Discount to future cash flow value
Intrinsic Value Based on Future Cash Flows
Fulgent Genetics's share price is below the future cash flow value, and at a moderate discount (> 20%).
Fulgent Genetics's share price is below the future cash flow value, but not at a substantial discount (< 40%).
Price Based on Earnings
Fulgent Genetics is loss making, we can't compare its value to the US Healthcare industry average.
Fulgent Genetics is loss making, we can't compare the value of its earnings to the United States of America market.
Price Based on Expected Growth
Unable to calculate PEG ratio for Fulgent Genetics, we can't assess if its growth is good value.
Price Based on Value of Assets
Fulgent Genetics is overvalued based on assets compared to the US Healthcare industry average.
Next Steps
Future Growth
How is Fulgent Genetics expected to perform in the next 1 to 3 years based on estimates from 2 analysts?
153.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Fulgent Genetics's revenue is expected to grow significantly at over 20% yearly.
Fulgent Genetics's earnings are expected to grow significantly at over 20% yearly.
Fulgent Genetics's revenue growth is expected to exceed the United States of America market average.
Fulgent Genetics's earnings growth is expected to exceed the United States of America market average.
Fulgent Genetics's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Earnings per Share Growth Estimates
Future Return on Equity
Fulgent Genetics is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
Next Steps
Past Performance
How has Fulgent Genetics performed over the past 5 years?
13.9%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Fulgent Genetics does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
Unable to compare Fulgent Genetics's 1-year earnings growth to the 5-year average as it is not currently profitable.
Unable to compare Fulgent Genetics's 1-year growth to the US Healthcare industry average as it is not currently profitable.
Return on Equity
It is difficult to establish if Fulgent Genetics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
Return on Assets
It is difficult to establish if Fulgent Genetics has efficiently used its assets last year compared to the US Healthcare industry average (Return on Assets) as it is loss-making.
Return on Capital Employed
It is difficult to establish if Fulgent Genetics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Next Steps
Financial Health
How is Fulgent Genetics's financial position?
Financial Position Analysis
Fulgent Genetics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Fulgent Genetics's cash and other short term assets cover its long term commitments.
Debt to Equity History and Analysis
Fulgent Genetics's level of debt (0%) compared to net worth is satisfactory (less than 40%).
Unable to establish if Fulgent Genetics's debt level has increased without past 5-year debt data.
Balance Sheet
Low level of unsold assets.
Debt is covered by short term assets, assets are 7.8351374517179E+16x debt.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Whilst loss making Fulgent Genetics has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
Whilst loss making Fulgent Genetics has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 44.2% per year.
Next Steps
Dividend
What is Fulgent Genetics's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate Fulgent Genetics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Fulgent Genetics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Fulgent Genetics has not reported any payouts.
Unable to verify if Fulgent Genetics's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Fulgent Genetics has not reported any payouts.
Future Payout to Shareholders
No need to calculate the sustainability of Fulgent Genetics's dividends in 3 years as they are not expected to pay a notable one for United States of America.
Next Steps
Management
What is the CEO of Fulgent Genetics's salary, the management and board of directors tenure and is there insider trading?
3.3yrs
Average management tenure
CEO
Ming Hsieh (63yo)
3.3yrs
Tenure
US$240,000
Compensation
Mr. Ming Hsieh is the Founder of Fulgent Genetics, Inc. and has been its President & Chief Executive Officer since May 2016 and served as its Manager. Mr. Hsieh serves as President at Fulgent Therapeutics, ...
CEO Compensation Analysis
Ming's remuneration is lower than average for companies of similar size in United States of America.
Ming's compensation has been consistent with company performance over the past year, both up more than 20%.
Management Age and Tenure
3.3yrs
Average Tenure
52yo
Average Age
The tenure for the Fulgent Genetics management team is about average.
Board Age and Tenure
3.0yrs
Average Tenure
65yo
Average Age
The tenure for the Fulgent Genetics board of directors is about average.
Insider Trading
Fulgent Genetics individual insiders have only sold shares in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Chief Financial Officer Chief Financial Officer |
| Shares | 12,389 |
| Max Price | US$11.52 |
| Entity | Individual |
| Role | Chief Financial Officer Chief Financial Officer |
| Shares | 1,404 |
| Max Price | US$5.50 |
| Entity | Individual |
| Role | Chief Executive Officer Chairman |
| Shares | 8,739 |
| Max Price | US$4.95 |
| Entity | Individual |
| Role | Chief Financial Officer Chief Financial Officer |
| Shares | 1,165 |
| Max Price | US$4.67 |
| Entity | Individual |
| Role | Chief Executive Officer Chairman |
| Shares | 10,880 |
| Max Price | US$3.59 |
| Entity | Individual |
| Role | Chief Financial Officer Chief Financial Officer |
| Shares | 1,446 |
| Max Price | US$3.50 |
| Entity | Individual |
| Role | Chief Executive Officer Chairman |
| Shares | 10,000 |
| Max Price | US$3.36 |
Ownership Breakdown
Management Team
Paul Kim (52yo)
Chief Financial Officer
- Tenure: 3.7yrs
- Compensation: US$241.12k
Ming Hsieh (63yo)
Chairman
- Tenure: 3.3yrs
- Compensation: US$240.00k
Harry Gao (52yo)
Chief Scientific Officer & Laboratory Director
- Tenure: 3yrs
- Compensation: US$216.30k
Board Members
John Bolger (72yo)
Independent Director
- Tenure: 3yrs
- Compensation: US$72.60k
Ming Hsieh (63yo)
Chairman
- Tenure: 3.3yrs
- Compensation: US$240.00k
Yun Yen (64yo)
Independent Director
- Tenure: 3yrs
- Compensation: US$53.50k
Mulé Mulay (66yo)
Independent Director
- Tenure: 3yrs
- Compensation: US$70.10k
Linda Marsh
Director
- Tenure: 0.08yrs
Company Information
Fulgent Genetics, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Fulgent Genetics, Inc.
- Ticker: FLGT
- Exchange: NasdaqGM
- Founded: 2011
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: US$204.272m
- Shares outstanding: 18.49m
- Website: https://www.fulgentgenetics.com
Number of Employees
Location
- Fulgent Genetics, Inc.
- 4978 Santa Anita Avenue
- Suite 205
- Temple City
- California
- 91780
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| FLGT | NasdaqGM (Nasdaq Global Market) | Yes | Common Stock | US | USD | Sep 2016 |
Biography
Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/09/19 01:02 |
| End of Day Share Price | 2019/09/18 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.